



1631

PATENT

Attorney Docket No. 896034605001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Elizabeth K. Barber
Serial No. : 09/966,264
Filed : September 28, 2001
Title : **GENE EXPRESSION CONTROL DNA
ELEMENT AND ASSOCIATED PROTEIN**
Group Art Unit : 1631
Examiner : Mary K. Zeman

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This application claims the benefit of U.S. Provisional Application, Serial No. 60/237,079, filed September 30, 2000.

This statement is submitted in compliance with 37 CFR 1.56. A list of patent(s) and/or publications is set forth on the attached PTO-1449. A copy of each item listed is enclosed.

Any additional fees required for the proper filing of this Information Disclosure Statement should be withdrawn from the Jones Day Deposit Account No. 50-1432, Ref. 896034-605001.


Respectfully submitted,

Barbara E. Arndt, Ph.D.
Reg. No. 37,768

Jones Day
North Point
901 Lakeside Avenue
Cleveland, Ohio 44114
(216) 586-7575

I hereby certify that this correspondence
is being deposited today with the United
States Postal Service as first class mail in
an envelope addressed to: Commissioner for
Patents, P.O. Box 1450, Alexandria, VA
22313-1450

on Dec 9/03
By: B. E. Arndt

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
896034605001SERIAL NO.
09/966,264INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

Elizabeth K. Barber

FILING DATE GROUP
September 28, 2001 1631

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/SUBCLASS	FILING DATE
---------------------	--------------------	------	------	----------------	-------------

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
---------------------	-----------------	------	---------	-------	----------	-----------------------

EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
---------------------	-----------------	--

Atkinson, J. and R. Martin. Mutations to nonsense codons in human genetic disease: implications for gene therapy by nonsense suppressor tRNAs. *Nucleic Acids Research* 22(8), 1327-1334 (1994).

Buvoli, M. et al. Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes. *Molecular and Cellular Biology* 20(9), 3116-3124 (May 2000).

Kaufman, Randal J. Correction of genetic disease by making sense from nonsense. *Journal of Clinical Investigation* 104(4), 367-368 (August 1999).

Kessler, P.D. et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. *PNAS USA* 93, 14082-14087 (1996).

Kidwell M.G. and A.R. Wattam. An important step forward in the genetic manipulation of mosquito vectors of human disease. *PNAS* 95(7), 3349-3350 (March 1998).

Haecker, S.E. et al. *In vivo* expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. *Human Gene Therapy* 7, 1907-1914 (1996).

Miralles, V.J. et al. The adenovirus inverted terminal repeat functions as an enhancer in a cell-free system. *J. Biol. Chem.* 264(18), 10763-10772 (1989).

Passos-Bueno, M.R. et al. Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. *Human Molecular Genetics* 3(6), 919-922 (1994).

Proudfoot, N.J. Transcriptional interference and termination between duplicated β -globin gene constructs suggests a novel mechanism for gene regulation. *Nature* 322, 562-565 (1986).

Stedman, H. et al. Clinical protocol: phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: \square , \square , \square , \square -sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. *Human Gene Therapy* 11, 777-790 (March 2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.